U008 Immunology for Dermies: from Autoimmune to Autoinflammatory
DESCRIPTION
This is one of two companion sessions on Immunology for Dermies. B cell immunology pertinent to the trainee and practicing medical dermatologist will be reviewed from a clinical perspective through a discussion of 1) B cell- and antibody-mediated skin disease, and 2) B cell-targeted and monoclonal antibody-based therapies used in dermatology. Laboratory tests pertinent to dermatology based on B cell biology and antibody technology will also be discussed. Topics to be covered include why ANCA vasculitis presents differently than small-vessel vasculitis, why rituximab and omalizumab sometimes fail, and why order a rheumatoid factor when concerned for cryoglobulinemia, among many others.
LEARNING OBJECTIVES
Provide an overview of B cell development and function.
Apply basic principles of B cell immunology to clinical practice.
Explain the limits of B cell- and antibody-targeted therapies.
SCHEDULE
7:30 AM
B cell Immunology for the Clinical Dermatologist
Christopher T Richardson, PhD, MD, FAAD
DIRECTORS
Christopher T Richardson, PhD, MD, FAAD
Danielle Tartar, MD, PhD, FAAD
DISCLOSURES
Christopher T Richardson, PhD, MD, FAAD
AstraZeneca – Investigator(Grants/Research Funding); Incyte Corporation – Investigator(Grants/Research Funding); Merck – Consultant (1099 relationship)(Fees); Ribon Therapeutics – Investigator(Grants/Research Funding);
Danielle Tartar, MD, PhD, FAAD
No financial relationships exist with ineligible companies.